{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:12:12Z","timestamp":1789135932271,"version":"build-2803163510"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Voriconazole exhibits substantial interindividual pharmacokinetic variability, largely driven by cytochrome P450 enzymes, particularly CYP2C19 and CYP3A4. Although pharmacogenetics plays a key role in predicting voriconazole exposure, systemic inflammation may transiently suppress CYP activity, leading to inflammation-induced phenoconversion. This mechanism can cause clinically relevant drug overexposure even in patients genetically predicted to be normal or rapid metabolizers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The authors describe the case of an adult patient receiving voriconazole who developed marked drug overexposure despite carrying a CYP2C19 rapid metabolizer genotype. Therapeutic drug monitoring, pharmacogenetic testing, and inflammatory biomarker assessment were performed. Clinical characteristics, laboratory parameters, and voriconazole plasma concentrations were evaluated to determine the impact of inflammation on drug metabolism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Voriconazole trough concentrations were markedly elevated and inconsistent with the genotype-predicted metabolic profile. This overexposure occurred concomitantly with a significant inflammatory state, reflected by increased C-reactive protein levels. No clinically relevant drug\u2013drug interactions or hepatic dysfunction were identified. As inflammatory markers progressively decreased, voriconazole concentrations declined accordingly, indicating reversible suppression of CYP-mediated metabolic capacity. These findings are consistent with inflammation-induced phenoconversion, whereby cytokine-mediated downregulation of CYP2C19 and CYP3A4 overrides genetically determined enzyme activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This case highlights the importance of an integrated approach to voriconazole therapy that combines pharmacogenetics, inflammatory status, and therapeutic drug monitoring. Recognizing inflammation-induced phenoconversion as a dynamic determinant of drug metabolism may improve the safety and efficacy of antifungal treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001493","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:00:18Z","timestamp":1781611218000},"page":"694-697","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Unexpected Voriconazole Overexposure in a CYP2C19 Rapid Metabolizer Due to Inflammation-Induced Phenoconversion: A Short Communication"],"prefix":"10.1097","volume":"48","author":[{"given":"Guillaume","family":"Drevin","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, University Hospital of Angers, Angers, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Picard","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, University Hospital of Limoges, Limoges, France;"},{"name":"University of Limoges, Faculty of Pharmacy, Limoges, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Briet","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, University Hospital of Angers, Angers, France;"},{"name":"University of Angers, Angers, France; and"},{"name":"MitoVasc Unit, Team Carme, SFR ICAT, University of Angers, UMR, CNRS 6015, Inserm U1083, Angers, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Abbara","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, University Hospital of Angers, Angers, France;"},{"name":"University of Limoges, Faculty of Pharmacy, Limoges, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1517\/14656561003649555","article-title":"Pharmacoeconomics of voriconazole","volume":"11","author":"Rubio-Terr\u00e9s","year":"2010","journal-title":"Expert Opin Pharmacother."},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3390\/jof7110925","article-title":"The use of voriconazole as primary prophylaxis for invasive fungal infections in patients undergoing allogeneic stem cell transplantation: a single center's experience","volume":"7","author":"Atoui","year":"2021","journal-title":"J Fungi (Basel)."},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s40262-023-01274-y","article-title":"Towards model-informed precision dosing of voriconazole: challenging published voriconazole nonlinear mixed-effects models with real-world clinical data","volume":"62","author":"Kluwe","year":"2023","journal-title":"Clin Pharmacokinet."},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/FPC.0000000000000276","article-title":"PharmGKB summary: voriconazole pathway, pharmacokinetics","volume":"27","author":"Barbarino","year":"2017","journal-title":"Pharmacogenet Genomics."},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"7475","DOI":"10.2147\/IDR.S391022","article-title":"Central nervous system toxicity of voriconazole: risk factors and threshold \u2013 a retrospective cohort study","volume":"15","author":"Yang","year":"2022","journal-title":"Infect Drug Resist."},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"1326776","DOI":"10.3389\/fphar.2024.1326776","article-title":"From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice","volume":"15","author":"Shubbar","year":"2024","journal-title":"Front Pharmacol."},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/bcp.70320","article-title":"Navigating therapeutic challenges: voriconazole pharmacokinetics and CYP2C19 genetic polymorphism \u2013 a case report and literature review","volume":"92","author":"Ahmer","year":"2026","journal-title":"Br J Clin Pharmacol."},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet."},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/00498254.2016.1271960","article-title":"Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes","volume":"47","author":"Shao","year":"2017","journal-title":"Xenobiotica"},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00228-010-0869-3","article-title":"Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism","volume":"66","author":"Shi","year":"2010","journal-title":"Eur J Clin Pharmacol."},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1128\/AAC.00791-07","article-title":"Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis","volume":"51","author":"Weiler","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1124\/dmd.114.061093","article-title":"Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine","volume":"43","author":"Shah","year":"2015","journal-title":"Drug Metab Dispos."},{"key":"R14-20260911","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bcp.12441","article-title":"Addressing phenoconversion: the Achilles' heel of personalized medicine","volume":"79","author":"Shah","year":"2015","journal-title":"Br J Clin Pharmacol."},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/cts.12758","article-title":"CYP2C9 and CYP2C19: deep mutational scanning and functional characterization of genomic missense variants","volume":"13","author":"Zhang","year":"2020","journal-title":"Clin Transl Sci."},{"key":"R17-20260911","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2217\/pgs-2017-0173","article-title":"Pharmacogenetic of voriconazole antifungal agent in pediatric patients","volume":"19","author":"Allegra","year":"2018","journal-title":"Pharmacogenomics"},{"key":"R18-20260911","doi-asserted-by":"crossref","first-page":"e00665","DOI":"10.1002\/prp2.665","article-title":"Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections","volume":"8","author":"Chuwongwattana","year":"2020","journal-title":"Pharmacol Res Perspect."},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"e00935","DOI":"10.1002\/prp2.935","article-title":"Impact of polymorphisms of pharmacokinetics-related genes and the inflammatory response on the metabolism of voriconazole","volume":"10","author":"Aiuchi","year":"2022","journal-title":"Pharmacol Res Perspect."},{"key":"R20-20260911","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jare.2020.12.003","article-title":"Rare variants discovery by extensive whole-genome sequencing of the Han Chinese population in Taiwan: applications to cardiovascular medicine","volume":"30","author":"Juang","year":"2021","journal-title":"J Adv Res."},{"key":"R21-20260911","doi-asserted-by":"crossref","first-page":"733935","DOI":"10.3389\/fphar.2021.733935","article-title":"Influence of inflammation on cytochromes P450 activity in adults: a systematic review of the literature","volume":"12","author":"Lenoir","year":"2021","journal-title":"Front Pharmacol."},{"key":"R22-20260911","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3390\/antibiotics12040764","article-title":"Impact of inflammation on voriconazole exposure in critically ill patients affected by probable COVID-19-associated pulmonary aspergillosis","volume":"12","author":"Gatti","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"R23-20260911","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1128\/AAC.03820-14","article-title":"Inflammation is associated with voriconazole trough concentrations","volume":"58","author":"Van Wanrooy","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"R24-20260911","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jac\/dkw349","article-title":"Voriconazole metabolism is influenced by severe inflammation: a prospective study","volume":"72","author":"Veringa","year":"2017","journal-title":"J Antimicrob Chemother."},{"key":"R25-20260911","doi-asserted-by":"crossref","first-page":"1455721","DOI":"10.3389\/fphar.2024.1455721","article-title":"Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: a population pharmacokinetics analysis","volume":"15","author":"Ling","year":"2024","journal-title":"Front Pharmacol."},{"key":"R26-20260911","doi-asserted-by":"crossref","first-page":"e13887","DOI":"10.1111\/cts.13887","article-title":"Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole","volume":"17","author":"Klomp","year":"2024","journal-title":"Clin Transl Sci."},{"key":"R27-20260911","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2133\/dmpk.DMPK-13-NT-007","article-title":"A case-report of unpredictable and massive voriconazole intoxication in a patient with extensive CYP2C19 and CYP2C9 polymorphisms","volume":"28","author":"Lemaitre","year":"2013","journal-title":"Drug Metab Pharmacokinet."},{"key":"R28-20260911","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3109\/03602539709002246","article-title":"Regulation of cytochromes P450 during inflammation and infection","volume":"29","author":"Morgan","year":"1997","journal-title":"Drug Metab Rev."},{"key":"R29-20260911","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2174\/1389200043335559","article-title":"Cytochrome P450 regulation and drug biotransformation during inflammation and infection","volume":"5","author":"Renton","year":"2004","journal-title":"Curr Drug Metab."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:00:55Z","timestamp":1789135255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001493","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"2026-01-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}